<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Vis</journal-id><journal-id journal-id-type="publisher-id">MV</journal-id><journal-title>Molecular Vision</journal-title><issn pub-type="epub">1090-0535</issn><publisher><publisher-name>Molecular Vision</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">85</article-id><article-id pub-id-type="publisher-id">2009MOLVIS0090</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Two novel <italic>FBN1</italic> mutations associated with ectopia lentis and marfanoid habitus in two Chinese families</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Liming</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Liang</surname><given-names>Ting</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Jianzhen</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Hui</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Dandan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Qi</surname><given-names>Yanhua</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><aff id="aff1"><label>1</label>Department of Ophthalmology, Harbin Medical University the 2nd Affiliated Hospital, Harbin, China</aff><aff id="aff2"><label>2</label>Center of Integrative Biology, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China</aff></contrib-group><author-notes><fn><p>The first two authors contributed equally to this work.</p></fn><corresp id="cor1">Correspondence to: Dr. Yanhua Qi, Department of Ophthalmology, Harbin Medical University the 2nd Affiliated Hospital, 246 Xuefu Road, Harbin, Heilongjiang, 150086, China; Phone: 86-451-86605851; FAX: 86-451-86605116; email: <email xlink:href="qi_yanhua@yahoo.com">qi_yanhua@yahoo.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>23</day><month>4</month><year>2009</year></pub-date><volume>15</volume><fpage>826</fpage><lpage>832</lpage><history><date date-type="received"><day>26</day><month>3</month><year>2009</year></date><date date-type="accepted"><day>17</day><month>4</month><year>2009</year></date></history><permissions><copyright-year>2009</copyright-year><copyright-holder>Molecular Vision</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title>Purpose</title><p>To identify the molecular defects in the fibrillin-1 gene (<italic>FBN1</italic>) in two Chinese families with ectopia lentis (EL) and marfanoid habitus.</p></sec><sec sec-type="methods"><title>Methods</title><p>Five patients and eight non-carriers in the two families underwent complete physical, ophthalmic, and cardiovascular examinations. Genomic DNA was extracted from leukocytes of venous blood of these individuals in the families as well as 100 healthy normal controls. Polymerase chain reaction (PCR) amplification and direct sequencing of all 65 coding exons of <italic>FBN1</italic> were analyzed. The functional consequences of the mutations were analyzed with various genomic resources.</p></sec><sec><title>Results</title><p>Two novel mutations of <italic>FBN1</italic> were identified in our study. One is a splice defect in intron 17 (IVS 17&#x02013;1G&#x0003e;T) adjacent to exon 18. The other is c.6182G&#x0003e;T in exon 50, which results in the substitution of cysteine by phenylalanine at codon 2,061 (p. C2061F). We provided strong evidences that the splice mutation would potentially lead to the skipping of exons after intron 17 and that the missense mutation at codon 2,061 (p. C2061F) would destroy a disulfide bond.</p></sec><sec><title>Conclusions</title><p>We detected two novel mutations in <italic>FBN1</italic>. Our results expand the mutation spectrum of <italic>FBN1</italic> and help in the study of the molecular pathogenesis of Marfan syndrome and Marfan-related disorders.</p></sec></abstract><custom-meta-wrap><custom-meta><meta-name>GalleyStatus</meta-name><meta-value>Export to XML</meta-value></custom-meta><custom-meta><meta-name>corr-author</meta-name><meta-value>Qi</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Ectopia lentis (EL; OMIM <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=129600">129600</ext-link>) is an inherited connective disorder characterized by lens dislocation, often connected with stretched or discontinuous zonular filaments [<xref ref-type="bibr" rid="r1">1</xref>]. In most cases, EL occurs as one symptom of Marfan syndrome (MFS; OMIM <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=154700">154700</ext-link>), a genetic autosomal dominant disorder that is characterized by manifestations mainly involving the cardiovascular, skeletal, and ocular systems [<xref ref-type="bibr" rid="r2">2</xref>]. According to the Ghent nosology, a clinical diagnosis of MFS requires the involvement of all three systems with two major diagnostic manifestations [<xref ref-type="bibr" rid="r3">3</xref>]. Other disorders such as isolated EL or predominant EL with some skeletal features belong to Marfan-related disorders.</p><p>Both Marfan syndrome and Marfan-related disorders mainly result from mutations in the fibrillin-1 gene (<italic>FBN1</italic>) [<xref ref-type="bibr" rid="r4">4</xref>]. <italic>FBN1</italic> encodes a 320 kDa glycoprotein consisting of 2,871 amino acids and is located on chromosome 15q21. FBN1 is mainly composed of three types of repeated modules. The first one is the epidermal growth factor (EGF)-like module, which includes six cysteine residues. There are 47 such modules, and most of them are calcium binding (cb) EGF-like modules. The second type is called transforming growth factor &#x003b2;1-binding (or TB) protein-like module (TGF &#x003b2;1-BP-like module, or 8-Cys/TB), which is found seven times in FBN1. This module contains eight cysteine residues that form four disulfide bonds. The last one is a hybrid module, which occurs twice [<xref ref-type="bibr" rid="r5">5</xref>].</p><p>In this study, we analyzed two Chinese families with EL and marfanoid habitus and detected two novel heterozygous mutations in <italic>FBN1</italic> . In each family, the mutation found cosegregated in the patients and was not observed in any of the healthy family members.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients and clinical data</title><p>In our study, the patients from two Chinese families with ectopia lentis and marfanoid habitus were from the Heilongjiang province in northeastern China. Two patients and six non-carrier relatives in Family 1, three patients and two non-carrier relatives in Family 2, and 100 healthy normal controls were recruited for this study. The study was approved by the Institutional Review Board of Harbin Medical University (Harbin, China). After obtaining informed consent from all the participants, thorough physical, ophthalmic, and cardiovascular examinations were performed.</p></sec><sec><title>Genomic DNA preparation</title><p>Blood specimens (5 ml) were collected in EDTA, and genomic DNA was extracted by the TIANamp Blood DNA Kit (Tiangen Biltech Co. Ltd, Beijing, China).</p></sec><sec><title>Mutation screening</title><p>All coding exons of <italic>FBN1</italic> were amplified by polymerase chain reaction (PCR) using a set of 59 pairs of primers. The primers for exons 4, 5, 7, 11, 15, 22, 23, 31, 41, 44, 45, 51, and 52 were from those described by Li and coworkers [<xref ref-type="bibr" rid="r6">6</xref>]. The others are listed in <xref ref-type="table" rid="t1">Table 1</xref>. The PCR products were subsequently purified with a TIANgel Midi Purification Kit (Tiangen Biltech Co. Ltd) and sequenced with an ABI BigDye Terminator Cycle Sequencing kit v3.1 (ABI Applied Biosystems, Foster City, CA).</p><table-wrap id="t1" position="float"><label>Table 1</label><caption><title>Primers used for <italic>FBN1</italic> amplification.</title></caption><table frame="hsides" rules="groups"><col width="40" span="1"/><col width="190" span="1"/><col width="196" span="1"/><col width="112" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Exon</bold></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Forward primer (5&#x02032;&#x02192;3&#x02032;)</bold></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Reverse primer (5&#x02032;&#x02192;3&#x02032;)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Product length (bp)</bold></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GGATTTGTCTCTGTGTTGCAG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CTTGCCAAGGAGTCTTCCAC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">465<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CTGCCAGGATTCATCTTGCT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AACTTTGACAGGGTTTGACCA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">384<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TTGTGAGGGACCTGAGAACC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TTTGGGCAGAACAGAGAAGG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">340<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TGCATGATTCTGTCCCTGAA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">ATGCAGTCAGCGAAATTGTG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">452<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GCTGTTTCCAGGGACATGAT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AACCATGCATGCTGTTTGTC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">267<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GGGGCAGAGGTGTGAGTTAAT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CCCAAGTTTCCATTACATCTGC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">380<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">10<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TGACTTCTGTGGGCCTATGA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GAAGCCTCCCGTTTTTCTCT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">448<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">12<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GCTCAACCAGTCTTCAAATGG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CTTCCGGCATGGGTTATTTA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">398<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">13<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AATGGAGGGAGGGGGAAATA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AAATGGCAAGCTCTCCTAGC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">420<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">14<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">ATGCACATGCCAAAACTCAA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TCCCAAACCAAAATTCAAGG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">459<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">16<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CAGAGGCATTCCCTGTGAGT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AAGACCCCAAGAAGGCACAT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">407<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">17<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TGATGTGTGCAAAACCAAGG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CATCCCAGATACATGGCACA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">274<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">18<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CCTCCTGTAGCTCCTAAGGTCA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AAGTGTCCATTTGCCCAGTC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">348<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">19<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CAGGAGTTTTGCCTTTTTGC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TGGCATTCCAAAAGATAGCA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">308<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">20<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AGCCCAGCTTTACTGTGTGG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TTTTGCAGGAAAAGCTGACA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">313<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">21<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AATGTCAGCTTTTCCTGCAA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CCCATTCAGCAATATGTTCG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">437<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">24<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GGCAAGGATACTTACCCCAGA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AAAGTCCATGCTGGGATGAT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">506<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">25&#x02013;26<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AAAATGGTGGGCATTGAGAC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CCTCAGTCTCCCTCTGTTGC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">601<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">27&#x02013;28<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AAGATGGACACCCAGCAATG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AGCGATGAAAACAAAACTCAGA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">594<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">29<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GATCCCACCATGAGGGTAGA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AAAGCCTGGGCCCTAAACTA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">355<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">30<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CCCAATGGGCTAGTTTATGC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GCTCTCTTTGGAATGCTGGT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">444<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">32&#x02013;33<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TGGGAAGTTTGAAGGCAAGT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GCCTGAGAAATGTGGAATGC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">566<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">34<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TGCTGCACTGGAAAGTTGAT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GAAATGGTCAGCTGGAAACC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">382<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">35<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GAAGTGCCCAGATTGGTGTT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GTGACGGCCCTTGTGTAGTC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">344<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">36<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TCTCTGAAGTGGAAGACTGCAT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AGAATGGAATGTTTGGTGCTG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">352<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">37<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">ACGGTTTTTGAACAGTTCCTG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">ATTGGGAATAAGGTCCCCTCT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">400<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">38&#x02013;39<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TCAGACGGGCAGAGTAACAA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CCTGGCTATGTTCGTGTTTAGA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">556<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">40<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GAGAGGACACGGATGAATGAA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AACAAGACAGTGAAGGGATGC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">408<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">42<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TTCTTTGCTGACCCCTATCC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">ATTAGGTGGAGCTGCACAGG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">303<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">43<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GTCCCTATTGCCATCACCAC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TCCACACCATGCCCTTTACT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">411<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">46<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CCTGGTATCTTGCAGGGATG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CTGACTTCCTTTGCTGATGC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">323<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">47<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TGGCATTTCTTGTTTGGCTA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TTTTCCTCCAGGTTTCCAGA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">372<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">48<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GAAGTCATGCCAGTGGGAAC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CTTGCCAGAAGGATGAGACC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">325<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">49<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CCCTTTGTGTGTCCACATTG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CAGAGCTTTGCCATGTTTGA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">295<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">50<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">ATTGCTGTGGTCCTGAGAGG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TTACATCATGGCCAGTCTGC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">329<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">53<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AGCACTGCAGTCTGGATGTC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AATGATCAAATGGCCCATCA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">399<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">54<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GGAAATGGGAGACCACTTGA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">ATTCCAATTCCCAGCCTTCT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">371<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">55<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GCAGAAGGAAATACAGCCAGT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GGGTCTCGCCAAGAACAGTA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">372<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">56<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GAACAAAGGGAGGGAAGGAG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CAGTCATTACGGCATCTCCA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">389<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">57<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GCTTTCCCCTCTTGCTTCTT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GGCACATATTGCAACTCCA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">441<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">58&#x02013;59<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CACTGAAGTGACCCCCTACAT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AAGCACCTCCTGCCTGTAGA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">688<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">60<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AATCAAACGTGGAGCTGCTT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AAAGGCCAAATAAGGCCAAC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">382<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">61<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AGCGTTGTTGGCCTTATTTG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CCTGGGCTCAGATCTGCTAT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">356<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">62<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TAGGATGTGTAGGGGCCAGA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TTCAACCAGGTTAGGGCAAT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">349<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">63<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AGCCACCTCTGCCTGTCTTA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AAAGCATGGTTCTCCTCTGC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">473<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">64<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TCACAACTGCAAGGAACAGG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">ACACTTTGGAGCATCCTTGG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">362<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">65</td><td valign="top" align="left" rowspan="1" colspan="1">GCAGCATAAGGCAGAAAATTG</td><td valign="top" align="left" rowspan="1" colspan="1">TCACCTGTACCTTGCTTTGG</td><td valign="top" align="center" rowspan="1" colspan="1">667</td></tr></tbody></table><table-wrap-foot><p>Summary of the primers used for the amplification of <italic>FBN1</italic> exons. Sequences are given in the 5&#x02032;&#x02192;3&#x02032;direction.</p></table-wrap-foot></table-wrap></sec><sec><title>Information theory mutational analysis</title><p>The potential results of the G&#x02192;T transversion were estimated using information theory as described in the literature [<xref ref-type="bibr" rid="r7">7</xref>]. Briefly, potential splice sites were identified by the splice mutation analysis system based on information theory. Thus, the score of the site containing a mutant nucleotide would be significantly changed compared with that of the wild-type splice site. The analysis had been previously used for the interpretation of other mutations [<xref ref-type="bibr" rid="r8">8</xref>,<xref ref-type="bibr" rid="r9">9</xref>]. We used walker [<xref ref-type="bibr" rid="r10">10</xref>] visualization maps to present the predicted changes in binding sites.</p></sec><sec><title>Structure analysis</title><p>The protein structure file, 1apj, downloaded from the Protein data bank (<ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/home/home.do">PDB</ext-link>) database, demonstrates the solution structure of the transforming growth factor beta binding (TB) protein-like domain 6 of fibrillin (residues 2054&#x02013;2125) [<xref ref-type="bibr" rid="r11">11</xref>]. This structure was displayed with the <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/home/home.do">KiNG</ext-link> viewer to show the missense mutation at codon 2061.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Clinical findings</title><p>In the two families, all the patients (<xref ref-type="fig" rid="f1">Figure 1A</xref>, <xref ref-type="fig" rid="f2">Figure 2A</xref>) in our study showed similar clinical symptoms (<xref ref-type="table" rid="t2">Table 2</xref>). Bilateral lens dislocation was discovered in the five patients, and none of them displayed any abnormalities in the cardiovascular system by echocardiogram. However, in Family 2, individual I:2 died of congenital heart disease at the age of 30 years old with big hands according to the description of her daughter (II:2), and her granddaughter (III:1) also died of congenital heart disease only four days after birth. It was not clear whether they had any other abnormalities such as EL because they were deceased several years ago and no related medical records were available. As for the skeletal system, arachnodactyly was present in the five patients.</p><table-wrap id="t2" position="float"><label>Table 2</label><caption><title>Clinical details of the five patients from the two families.</title></caption><table frame="hsides" rules="groups"><col width="171" span="1"/><col width="54" span="1"/><col width="46" span="1"/><col width="43" span="1"/><col width="45" span="1"/><col width="45" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Manifestation</bold></th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1"><bold>Family 1</bold></th><th colspan="3" valign="top" align="center" scope="colgroup" rowspan="1"><bold>Family 2</bold></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Patient</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>II:5</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>III:4</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>II:2</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>II:3</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>III:2</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age (Years)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">39<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">11<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">24<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">20<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sex<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">F<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">F<hr/></td></tr><tr><td colspan="6" valign="top" align="center" scope="col" rowspan="1"><bold>Ocular system</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ectopia lentis<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">+<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Myopia<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">+<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Abnormally flat cornea<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Early development of cataract<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Strabismus<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">+<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Glaucoma<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Retina detachment<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td></tr><tr><td colspan="6" valign="top" align="center" scope="col" rowspan="1"><bold>Skeletal system</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Height (cm)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">193<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">153<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">168<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">174<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">107<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Arm span (cm)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">194<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">151<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">171<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">172<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">107<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">AS/H (normal&#x0003c;1.05)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.01<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.99<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.02<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.99<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Pectus carinatum<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Pectus excavatum<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Scoliosis<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Arachnodactyly<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">+<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">High palate with dental crowding<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Joint hypermobility<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Flatfoot<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td></tr><tr><td colspan="6" valign="top" align="center" scope="col" rowspan="1"><bold>Other manifestations</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hyperextensible skin<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hernia</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table><table-wrap-foot><p>Affected family members had bilateral ectopia lentis, and arachnodactyly. Abnormalities in the cardiovascular system were absent. Abbreviations: M: male; F: female; AS/H: arm span/height ratio; +: present, &#x02013;: absent.</p></table-wrap-foot></table-wrap></sec><sec><title>Mutation analysis</title><p>After direct sequencing of <italic>FBN1</italic> in the five patients, a splice defect in intron 17 (IVS 17-1G&#x0003e;T) adjacent to exon 18 (<xref ref-type="fig" rid="f1">Figure 1B</xref>) and a missense mutation involving the substitution of cysteine by phenylalanine in exon 50 (p.C2061F; <xref ref-type="fig" rid="f2">Figure 2B</xref>) were discovered in Family 1 and Family 2, respectively. Neither of the two mutations was detected in the healthy family members (<xref ref-type="fig" rid="f1">Figure 1C</xref>, <xref ref-type="fig" rid="f2">Figure 2C</xref>) or any of the 100 unrelated control subjects.</p><fig id="f1" fig-type="figure" position="float"><label>Figure 1</label><caption><p>A novel <italic>FBN1</italic> splice mutation in intron 17. <bold>A</bold>: The pedigree of Family 1 is shown. Squares and circles indicate males and females, respectively, and the darkened symbols represent the affected members. The patient above the arrow is the proband. An asterisk indicates the subject underwent clinical and molecular analyses. <bold>B</bold>: The partial nucleotide sequence of <italic>FBN1</italic> in an affected member is shown. A heterozygous change G&#x0003e;T (indicated by the arrow) was identified at the boundary of intron 17 and exon 18. <bold>C</bold>: The corresponding normal sequence in an unaffected family member is displayed by an arrow.</p></caption><graphic xlink:href="mv-v15-826-f1"/></fig><fig id="f2" fig-type="figure" position="float"><label>Figure 2</label><caption><p>A novel <italic>FBN1</italic> missense mutation in exon 50. <bold>A</bold>: The pedigree of Family 2 is shown. Slashed symbols denote that the subject is deceased. Symbols with a question mark in the center indicate that the member is not diagnosed clearly. <bold>B</bold>: A heterozygous G&#x0003e;T transversion (indicated by the arrow) resulted in the substitution of cysteine-2061 by phenylalanine (C2061F) in an affected subject. <bold>C</bold>: The corresponding normal sequence in an unaffected family member is shown by an arrow.</p></caption><graphic xlink:href="mv-v15-826-f2"/></fig></sec><sec><title>Potential functional consequences of the two mutations</title><p>The IVS 17&#x02013;1G&#x0003e;T mutation located at a highly conserved splice site of intron 17, which has canonical GT/AG ends (<xref ref-type="fig" rid="f3">Figure 3A</xref>). Information theory analysis revealed that the information contents (Ri) value decreased from 9.2 bits to 0.5 bits by the mutation (<xref ref-type="fig" rid="f3">Figure 3B</xref>). The cysteine residue at position 2,061 was also conserved among mammalian species (<xref ref-type="fig" rid="f4">Figure 4A</xref>). Structure analysis of the transforming growth factor &#x003b2; (TGF-&#x003b2;)-binding protein-like domain revealed that C2061 and C2083 formed one of the four disulfide bonds. (<xref ref-type="fig" rid="f4">Figure 4B</xref>) [<xref ref-type="bibr" rid="r11">11</xref>].</p><fig id="f3" fig-type="figure" position="float"><label>Figure 3</label><caption><p>Analysis of the splice mutaion in intron 17. <bold>A</bold>: The alignment of the FBN1 sequence with the corresponding segments in diverse species is displayed. The nucleotide G is conserved in FBN1 proteins from several species. The sequence was selected by <ext-link ext-link-type="uri" xlink:href="(http://genome.ucsc.edu/">UCSC Genome Browser</ext-link>. Note that <italic>FBN1</italic> is located at the minus strand, and the nucleotide sequence of this genomic region is represented by the plus strand. The 'Mammal Cons&#x02019; is a conservation measurement. <bold>B</bold>: The walker diagram of 3&#x02032; (acceptor) splice site in intron 17 and its adjacent sequence is shown. The wild-type sequence is at the top. Bases in splice sites are shown in the corresponding walker diagram. The arrow points to the mutant sequence with the G to T base change and shows the change from a positive contribution by the G to a near zero contribution of the T.</p></caption><graphic xlink:href="mv-v15-826-f3"/></fig><fig id="f4" fig-type="figure" position="float"><label>Figure 4</label><caption><p>Analysis of the missense mutation in exon 50. <bold>A</bold>: The alignment of the FBN1 sequence with the corresponding segments in diverse species is shown. The cysteine is conserved in FBN1 proteins from several species. The sequence was selected from the <ext-link ext-link-type="uri" xlink:href="http://www.uniprot.org/help/uniprotkb">UniProt Knowledge base</ext-link>. <bold>B</bold>: Structure analysis of the transforming growth factor-binding protein-like domains (8-Cys/TB) in human FBN1. &#x003b1;-helices and &#x003b2;-strands are shown with red and brown colors. The two residues (C2061 and C2083) are colored green. The disulfide bond is represented with a dotted line.</p></caption><graphic xlink:href="mv-v15-826-f4"/></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>In this study, we described two novel heterozygous mutations in <italic>FBN1</italic> (IVS 17&#x02013;1G&#x0003e;T and p.C2061F). Furthermore, we used various genomic resources to analyze the potential functional consequences of these two mutations.</p><p>In Family 1, it was a splice mutation in position 1 of the intron 17-exon 18 boundary in the domain of cb EGF-like number 07. EGF-like domains play a major role in the pathogenesis of fibrillinopathies containing 75% of all the <italic>FBN1</italic> mutations registered in the FBN1 Universal Mutation Database (<ext-link ext-link-type="uri" xlink:href="http://www.umd.be/FBN1/">UMD</ext-link>) database. Previously, Rogan et al. [<xref ref-type="bibr" rid="r12">12</xref>] showed that the minimum Ri value for a functional splice site was 2.4 in a study of over 100 splice sites. As for the splice mutation in our study, the Ri value decreased from 9.2 bits to 0.5 bits. The mutation of this base would be expected to disrupt the acceptor site and potentially lead to abnormal mRNA splicing and skipping of exons after intron 17. This also supports the observation that splice mutations often lead to a shortened protein, accounting for about 11%&#x02013;12% of the gene lesions in <italic>FBN1</italic> [<xref ref-type="bibr" rid="r5">5</xref>,<xref ref-type="bibr" rid="r13">13</xref>]. Interestingly, the c. 2168&#x02013;1G&#x0003e;T splice site mutation (in IVS 17) involved the same nucleotide of the c. 2168&#x02013;1G&#x0003e;A substitution previously described in <italic>FBN1</italic> [<xref ref-type="bibr" rid="r14">14</xref>].</p><p>Family 2 carried a missense mutation affecting cysteine residues in exon 50 in the domain of 8-Cys/TB number 06. This supports the previous studies that mutations involving cysteine substitution are usually associated with EL [<xref ref-type="bibr" rid="r13">13</xref>,<xref ref-type="bibr" rid="r15">15</xref>,<xref ref-type="bibr" rid="r16">16</xref>]. Each 8-Cys/TB module contains eight highly conserved cysteine residues holding TGF-&#x003b2; in an inactive complex in various tissues including the extracellular matrix [<xref ref-type="bibr" rid="r17">17</xref>]. Structure analysis showed C2061 and C2083 form one of the four disulfide bonds. Therefore, the substitution of cysteine by phenylalanine in this position was likely to destroy the disulfide bond and cause domain misfolding and structure instability. Recent studies demonstrated that increased TGF-&#x003b2; signaling contributed to selected symptoms of MFS [<xref ref-type="bibr" rid="r18">18</xref>] and could cause dysregulation of cytokine function in mouse models of MFS [<xref ref-type="bibr" rid="r19">19</xref>]. All above show that 8-Cys/TB domains also play an important role in the pathogenesis of fibrillinopathies.</p><p>Since <italic>FBN1</italic> cDNA was cloned and the first mutations of <italic>FBN1</italic> were identified in MFS patients in 1991 [<xref ref-type="bibr" rid="r20">20</xref>-<xref ref-type="bibr" rid="r22">22</xref>], currently more than 1,200 <italic>FBN1</italic> mutations have been described [<xref ref-type="bibr" rid="r23">23</xref>]. Most of them are missense mutations, and others are nonsense mutations, splice defect, deletions, and so on. In this study, we described two novel heterozygous mutations in <italic>FBN1</italic> in the Chinese patients with ectopic lentis and marfanoid habitus and analyzed the potential functional consequences of the two mutations. Our data further expand the mutation spectrum of <italic>FBN1</italic> and help in the study of molecular pathogenesis of Marfan syndrome and Marfan-related disorders.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors are grateful to all the patients and their families as well as to the normal volunteers for their participation in this study.</p></ack><ref-list><title>References</title><ref id="r1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dietz</surname><given-names>HC</given-names></name><name><surname>Pyeritz</surname><given-names>RE</given-names></name></person-group><article-title>Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders.</article-title><source>Hum Mol Genet</source><year>1995</year><volume>4</volume><fpage>1799</fpage><lpage>809</lpage><pub-id pub-id-type="pmid">8541880</pub-id></citation></ref><ref id="r2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Von Kodolitsch</surname><given-names>Y</given-names></name><name><surname>Robinson</surname><given-names>PN</given-names></name></person-group><article-title>Marfan syndrome: an update of genetics, medical and surgical management.</article-title><source>Heart</source><year>2007</year><volume>93</volume><fpage>755</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">17502658</pub-id></citation></ref><ref id="r3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De-Paepe</surname><given-names>A</given-names></name><name><surname>Devereux</surname><given-names>R</given-names></name><name><surname>Dietz</surname><given-names>H</given-names></name><name><surname>Hennekam</surname><given-names>R</given-names></name><name><surname>Pyeritz</surname><given-names>R</given-names></name></person-group><article-title>Revised diagnostic criteria for the Marfan syndrome.</article-title><source>Am J Med Genet</source><year>1996</year><volume>62</volume><fpage>417</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">8723076</pub-id></citation></ref><ref id="r4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>PN</given-names></name><name><surname>Booms</surname><given-names>P</given-names></name><name><surname>Katzke</surname><given-names>S</given-names></name><name><surname>Ladewig</surname><given-names>M</given-names></name><name><surname>Neumann</surname><given-names>L</given-names></name><name><surname>Palz</surname><given-names>M</given-names></name><name><surname>Pregla</surname><given-names>R</given-names></name><name><surname>Tiecke</surname><given-names>F</given-names></name><name><surname>Rosenberg</surname><given-names>T</given-names></name></person-group><article-title>Mutations of FBN1 and genotype-phenotype correlations in Marfan syndrome and related fibrillinopathies.</article-title><source>Hum Mutat</source><year>2002</year><volume>20</volume><fpage>153</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">12203987</pub-id></citation></ref><ref id="r5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Collod-B&#x000e9;roud</surname><given-names>G</given-names></name><name><surname>Boileau</surname><given-names>C</given-names></name></person-group><article-title>Marfan syndrome in the third Millennium.</article-title><source>Eur J Hum Genet</source><year>2002</year><volume>10</volume><fpage>673</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">12404097</pub-id></citation></ref><ref id="r6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>F</given-names></name><name><surname>Pang</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name></person-group><article-title>The Roles of Two Novel FBN1 Gene Mutations in the Genotype&#x02013;Phenotype Correlations of Marfan Syndrome and Ectopia Lentis Patients with Marfanoid Habitus.</article-title><source>Genet Test</source><year>2008</year><volume>12</volume><fpage>325</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">18471089</pub-id></citation></ref><ref id="r7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rogan</surname><given-names>PK</given-names></name><name><surname>Schneider</surname><given-names>TD</given-names></name></person-group><article-title>Using information content and base frequencies to distinguish mutations from genetic polymorphisms in splice junction recognition sites.</article-title><source>Hum Mutat</source><year>1995</year><volume>6</volume><fpage>74</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7550236</pub-id></citation></ref><ref id="r8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kannabiran</surname><given-names>C</given-names></name><name><surname>Rogan</surname><given-names>PK</given-names></name><name><surname>Basti</surname><given-names>S</given-names></name><name><surname>Rao</surname><given-names>GN</given-names></name><name><surname>Kaiser-Kupfer</surname><given-names>M</given-names></name><name><surname>Hejtmancik</surname><given-names>JF</given-names></name></person-group><article-title>Autosomal dominant zonular cataract with sutural opacities is associated with a splice mutation in the betaA3/A1-crystallin gene.</article-title><source>Mol Vis</source><year>1998</year><volume>4</volume><fpage>21</fpage><pub-id pub-id-type="pmid">9788845</pub-id></citation></ref><ref id="r9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hobson</surname><given-names>GM</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Sperle</surname><given-names>K</given-names></name><name><surname>Sistermans</surname><given-names>E</given-names></name><name><surname>Rogan</surname><given-names>PK</given-names></name><name><surname>Garbern</surname><given-names>JY</given-names></name><name><surname>Kolodny</surname><given-names>E</given-names></name><name><surname>Naidu</surname><given-names>S</given-names></name><name><surname>Cambi</surname><given-names>F</given-names></name></person-group><article-title>Splice site contribution in alternative splicing of PLP and DM20: molecular studies in oligodendrocytes.</article-title><source>Hum Mutat</source><year>2006</year><volume>27</volume><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">16287154</pub-id></citation></ref><ref id="r10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>TD</given-names></name></person-group><article-title>Sequence walkers: a graphical method to display how binding proteins interact with DNA or RNA sequences.</article-title><source>Nucleic Acids Res</source><year>1997</year><volume>25</volume><fpage>4408</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">9336476</pub-id></citation></ref><ref id="r11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Downing</surname><given-names>AK</given-names></name><name><surname>Knott</surname><given-names>V</given-names></name><name><surname>Handford</surname><given-names>PA</given-names></name></person-group><article-title>Solution structure of the transforming growth factor beta-binding protein-like module, a domain associated with matrix fibrils.</article-title><source>EMBO J</source><year>1997</year><volume>16</volume><fpage>6659</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">9362480</pub-id></citation></ref><ref id="r12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rogan</surname><given-names>PK</given-names></name><name><surname>Faux</surname><given-names>BM</given-names></name><name><surname>Schneider</surname><given-names>TD</given-names></name></person-group><article-title>Information analysis of human splice site mutations.</article-title><source>Hum Mutat</source><year>1998</year><volume>12</volume><fpage>153</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">9711873</pub-id></citation></ref><ref id="r13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Faivre</surname><given-names>L</given-names></name><name><surname>Collod-Beroud</surname><given-names>G</given-names></name><name><surname>Loeys</surname><given-names>BL</given-names></name><name><surname>Child</surname><given-names>A</given-names></name><name><surname>Binquet</surname><given-names>C</given-names></name><name><surname>Gautier</surname><given-names>E</given-names></name><name><surname>Callewaert</surname><given-names>B</given-names></name><name><surname>Arbustini</surname><given-names>E</given-names></name><name><surname>Mayer</surname><given-names>K</given-names></name><name><surname>Arslan-Kirchner</surname><given-names>M</given-names></name><name><surname>Kiotsekoglou</surname><given-names>A</given-names></name><name><surname>Comeglio</surname><given-names>P</given-names></name><name><surname>Marziliano</surname><given-names>N</given-names></name><name><surname>Dietz</surname><given-names>HC</given-names></name><name><surname>Halliday</surname><given-names>D</given-names></name><name><surname>Beroud</surname><given-names>C</given-names></name><name><surname>Bonithon-Kopp</surname><given-names>C</given-names></name><name><surname>Claustres</surname><given-names>M</given-names></name><name><surname>Muti</surname><given-names>C</given-names></name><name><surname>Plauchu</surname><given-names>H</given-names></name><name><surname>Robinson</surname><given-names>PN</given-names></name><name><surname>Ades</surname><given-names>LC</given-names></name><name><surname>Biggin</surname><given-names>A</given-names></name><name><surname>Benetts</surname><given-names>B</given-names></name><name><surname>Brett</surname><given-names>M</given-names></name><name><surname>Holman</surname><given-names>KJ</given-names></name><name><surname>De Backer</surname><given-names>J</given-names></name><name><surname>Coucke</surname><given-names>P</given-names></name><name><surname>Francke</surname><given-names>U</given-names></name><name><surname>De Paepe</surname><given-names>A</given-names></name><name><surname>Jondeau</surname><given-names>G</given-names></name><name><surname>Boileau</surname><given-names>C</given-names></name></person-group><article-title>Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study.</article-title><source>Am J Hum Genet</source><year>2007</year><volume>81</volume><fpage>454</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">17701892</pub-id></citation></ref><ref id="r14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Halliday</surname><given-names>DJ</given-names></name><name><surname>Hutchinson</surname><given-names>S</given-names></name><name><surname>Lonie</surname><given-names>L</given-names></name><name><surname>Hurst</surname><given-names>JA</given-names></name><name><surname>Firth</surname><given-names>H</given-names></name><name><surname>Handford</surname><given-names>PA</given-names></name><name><surname>Wordsworth</surname><given-names>P</given-names></name></person-group><article-title>Twelve novel FBN1 mutations in Marfan syndrome and Marfan related phenotypes test the feasibility of FBN1 mutation testing in clinical practice.</article-title><source>J Med Genet</source><year>2002</year><volume>39</volume><fpage>589</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">12161601</pub-id></citation></ref><ref id="r15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mizuguchi</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>N</given-names></name></person-group><article-title>Recent progress in genetics of Marfan syndrome and Marfan-associated disorders.</article-title><source>J Hum Genet</source><year>2007</year><volume>52</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">17061023</pub-id></citation></ref><ref id="r16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Loeys</surname><given-names>B</given-names></name><name><surname>De Backer</surname><given-names>J</given-names></name><name><surname>Van Acker</surname><given-names>P</given-names></name><name><surname>Wettinck</surname><given-names>K</given-names></name><name><surname>Pals</surname><given-names>G</given-names></name><name><surname>Nuytinck</surname><given-names>L</given-names></name><name><surname>Coucke</surname><given-names>P</given-names></name><name><surname>De Paepe</surname><given-names>A</given-names></name></person-group><article-title>Comprehensive molecular screening of the FBN1 gene favors locus homogeneity of classical Marfan syndrome.</article-title><source>Hum Mutat</source><year>2004</year><volume>24</volume><fpage>140</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15241795</pub-id></citation></ref><ref id="r17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gelb</surname><given-names>BD</given-names></name></person-group><article-title>Marfan&#x02019;s syndrome and related disorders&#x02014;more tightly connected than we thought.</article-title><source>N Engl J Med</source><year>2006</year><volume>355</volume><fpage>841</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">16929000</pub-id></citation></ref><ref id="r18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>CM</given-names></name><name><surname>Cheng</surname><given-names>A</given-names></name><name><surname>Myers</surname><given-names>LA</given-names></name><name><surname>Martinez-Murillo</surname><given-names>F</given-names></name><name><surname>Jie</surname><given-names>C</given-names></name><name><surname>Bedja</surname><given-names>D</given-names></name><name><surname>Gabrielson</surname><given-names>KL</given-names></name><name><surname>Hausladen</surname><given-names>JM</given-names></name><name><surname>Mecham</surname><given-names>RP</given-names></name><name><surname>Judge</surname><given-names>DP</given-names></name><name><surname>Dietz</surname><given-names>HC</given-names></name></person-group><article-title>TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome.</article-title><source>J Clin Invest</source><year>2004</year><volume>114</volume><fpage>1586</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">15546004</pub-id></citation></ref><ref id="r19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>PN</given-names></name><name><surname>Arteaga-Solis</surname><given-names>E</given-names></name><name><surname>Baldock</surname><given-names>C</given-names></name><name><surname>Collod-Beroud</surname><given-names>G</given-names></name><name><surname>Booms</surname><given-names>P</given-names></name><name><surname>De Paepe</surname><given-names>A</given-names></name><name><surname>Dietz</surname><given-names>HC</given-names></name><name><surname>Guo</surname><given-names>G</given-names></name><name><surname>Handford</surname><given-names>PA</given-names></name><name><surname>Judge</surname><given-names>DP</given-names></name><name><surname>Kielty</surname><given-names>CM</given-names></name><name><surname>Loeys</surname><given-names>B</given-names></name><name><surname>Milewicz</surname><given-names>DM</given-names></name><name><surname>Ney</surname><given-names>A</given-names></name><name><surname>Ramirez</surname><given-names>F</given-names></name><name><surname>Reinhardt</surname><given-names>DP</given-names></name><name><surname>Tiedemann</surname><given-names>K</given-names></name><name><surname>Whiteman</surname><given-names>P</given-names></name><name><surname>Godfrey</surname><given-names>M</given-names></name></person-group><article-title>The molecular genetics of Marfan syndrome and related disorders.</article-title><source>J Med Genet</source><year>2006</year><volume>43</volume><fpage>769</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">16571647</pub-id></citation></ref><ref id="r20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dietz</surname><given-names>HC</given-names></name><name><surname>Cutting</surname><given-names>GR</given-names></name><name><surname>Pyeritz</surname><given-names>RE</given-names></name><name><surname>Maslen</surname><given-names>CL</given-names></name><name><surname>Sakai</surname><given-names>LY</given-names></name><name><surname>Corson</surname><given-names>GM</given-names></name><name><surname>Puffenberger</surname><given-names>EG</given-names></name><name><surname>Hamosh</surname><given-names>A</given-names></name><name><surname>Nanthakumar</surname><given-names>EJ</given-names></name><name><surname>Curristin</surname><given-names>SM</given-names></name><name><surname>Stetton</surname><given-names>G</given-names></name><name><surname>Meyers</surname><given-names>DA</given-names></name><name><surname>Francomano</surname><given-names>CA</given-names></name></person-group><article-title>Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene.</article-title><source>Nature</source><year>1991</year><volume>352</volume><fpage>337</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">1852208</pub-id></citation></ref><ref id="r21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Godfrey</surname><given-names>M</given-names></name><name><surname>Vitale</surname><given-names>E</given-names></name><name><surname>Hori</surname><given-names>H</given-names></name><name><surname>Mattei</surname><given-names>MG</given-names></name><name><surname>Sarfarazi</surname><given-names>M</given-names></name><name><surname>Tsipouras</surname><given-names>P</given-names></name><name><surname>Ramirez</surname><given-names>F</given-names></name><name><surname>Hollister</surname><given-names>DW</given-names></name></person-group><article-title>Linkage of Marfan syndrome and a phenotypically related disorder to two different fibrillin genes.</article-title><source>Nature</source><year>1991</year><volume>352</volume><fpage>330</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">1852206</pub-id></citation></ref><ref id="r22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maslen</surname><given-names>CL</given-names></name><name><surname>Corson</surname><given-names>GM</given-names></name><name><surname>Maddox</surname><given-names>BK</given-names></name><name><surname>Glanville</surname><given-names>RW</given-names></name><name><surname>Sakai</surname><given-names>LY</given-names></name></person-group><article-title>Partial sequence of a candidate gene for the Marfan syndrome.</article-title><source>Nature</source><year>1991</year><volume>352</volume><fpage>334</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">1852207</pub-id></citation></ref><ref id="r23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Attanasio</surname><given-names>M</given-names></name><name><surname>Lapini</surname><given-names>I</given-names></name><name><surname>Evangelisti</surname><given-names>L</given-names></name><name><surname>Lucarini</surname><given-names>L</given-names></name><name><surname>Giusti</surname><given-names>B</given-names></name><name><surname>Porciani</surname><given-names>MC</given-names></name><name><surname>Fattori</surname><given-names>R</given-names></name><name><surname>Anichini</surname><given-names>C</given-names></name><name><surname>Abbate</surname><given-names>R</given-names></name><name><surname>Gensini</surname><given-names>GF</given-names></name><name><surname>Pepe</surname><given-names>G</given-names></name></person-group><article-title>FBN1 mutation screening of patients with Marfan syndrome and related disorders: detection of 46 novel FBN1 mutations.</article-title><source>Clin Genet</source><year>2008</year><volume>74</volume><fpage>39</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">18435798</pub-id></citation></ref></ref-list></back></article> 